Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,384,224 papers from all fields of science
Search
Sign In
Create Free Account
ON 01910
Known as:
ON-01910
, ON01910
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (2)
Glycine
Sulfones
Narrower (2)
ON 01910.Na
rigosertib
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell Carcinoma
V. S. Atanasova
,
C. Pourreyron
,
+18 authors
A. South
Clinical Cancer Research
2019
Corpus ID: 73514248
Purpose: Squamous cell carcinoma (SCC) of the skin is the leading cause of death in patients with the severe generalized form of…
Expand
2018
2018
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
P. Dietrich
,
K. Freese
,
A. Mahli
,
W. Thasler
,
C. Hellerbrand
,
A. Bosserhoff
Oncotarget
2018
Corpus ID: 20393755
Inhibition of RAS-RAF-ERK-signaling is a major mechanism mediated by the multi-kinase inhibitors sorafenib and regorafenib, the…
Expand
2014
2014
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities…
Tiangong Lu
,
Aik Wye Goh
,
+16 authors
Shudong Wang
Journal of medicinal chemistry
2014
Corpus ID: 29802144
ON01910.Na is a highly effective anticancer agent that induces mitotic arrest and apoptosis. Clinical studies with ON01910 in…
Expand
2013
2013
A Novel Anti-Tumor Inhibitor Identified by Virtual Screen with PLK1 Structure and Zebrafish Assay
Jing Lu
,
Shengchang Xin
,
+7 authors
Shuo Lin
PloS one
2013
Corpus ID: 16845783
Polo-like kinase 1 (PLK1), one of the key regulators of mitosis, is a target for cancer therapy due to its abnormally high…
Expand
2012
2012
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy
Silpa Nuthalapati
,
Q. Zhou
,
+5 authors
J. Gallo
Pharmaceutical Research
2012
Corpus ID: 15145715
ABSTRACTPurposeTo evaluate a mitotic inhibitor, ON01910.Na, as a potential chemotherapeutic agent for brain tumors using a series…
Expand
2011
2011
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.
Silpa Nuthalapati
,
P. Guo
,
Q. Zhou
,
M. Reddy
,
E. Reddy
,
J. Gallo
Journal of pharmaceutical and biomedical analysis
2011
Corpus ID: 8285085
2010
2010
Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
Hanbing Zhong
,
Shengchang Xin
,
+5 authors
Shuo Lin
Molecular bioSystems
2010
Corpus ID: 1168557
During the preclinical drug discovery process it remains a challenge to enable early elimination of candidate molecules that may…
Expand
Review
2010
Review
2010
New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer
A. Brüning
,
I. Mylonas
Archives of Gynecology and Obstetrics
2010
Corpus ID: 11847741
IntroductionOvarian cancer is a difficult to treat cancer entity with a high relapse rate. After initial surgery and chemotherapy…
Expand
Review
2009
Review
2009
BI 6727 , APolo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad
DorotheaRudolph
,
M. Steegmaier
,
+6 authors
R. Adolf
2009
Corpus ID: 45323107
Purpose:Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced andmetastatic cancers.To…
Expand
Highly Cited
2005
Highly Cited
2005
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
K. Gumireddy
,
M. Reddy
,
+6 authors
E. Reddy
Cancer cell
2005
Corpus ID: 39052903
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE